Loading stock data…
OKUR
$4.73-0.54 (-10.25%)
Market ClosedLast close May 1
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OnKure Therapeutics, Inc. in the Healthcare sector is trading at $4.73. The stock is currently near its 52-week high of $5.38, remaining 54.1% above its 200-day moving average. Technical signals show neutral RSI of 56 and bearish MACD signal, explaining why OKUR maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.73
Potential Upside
5%
Whystock Fair Value$4.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Mean target$20.20+327.1%
Range$11.00 – $30.00
Fundamentals
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-2...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$205.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-105.93%
Volume
Today's trading volume
186,075
Recent News
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Thermo Fisher heads into Q1 earnings with Life Sciences Solutions growth in focus, as bioproduction strength and new innovations may drive results.
Promising Penny Stocks To Watch In December 2025
As the Federal Reserve's meeting unfolds, investors are closely monitoring potential interest rate cuts that could influence market dynamics. Amid these developments, penny stocks continue to capture attention as a viable investment area, despite their seemingly outdated label. These smaller or newer companies can offer unique opportunities for growth and value, especially when they demonstrate strong financial resilience.
3 Promising Penny Stocks With Market Caps Under $200M
As the U.S. stock market shows signs of resilience with major indices like the Nasdaq and S&P 500 posting gains, investors are increasingly looking for opportunities beyond the usual tech giants. Penny stocks, a term that might seem outdated, still represent a compelling investment area by offering access to smaller or newer companies at lower price points. When these stocks are supported by strong financials and solid fundamentals, they can provide potential growth opportunities without many...
Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky
NasdaqGM:OKUR 1 Year Share Price vs Fair Value Explore OnKure Therapeutics's Fair Values from the Community and select...